

**Brand Name:** Atacand

**Generic:** candesartan cilexetil


**Type:** small molecule

**Year Accepted/Phase:** 1998

### **Mechanism:**

Candesartan blocks the binding of angiotensin II to its receptors, leading to vasodilation and reduced secretion of aldosterone, resulting in decreased blood pressure.

### **Chemical Structure:**



### **Indication:**

Atacand is indicated for the treatment of hypertension and heart failure.

## **Clinical trials:**

### **CHARM-Alternative Trial (Phase III)**

**Pubmed:** <https://pubmed.ncbi.nlm.nih.gov/15492298/>

**Purpose:** Compare the efficacy and safety of candesartan to placebo in patients with heart failure intolerant to angiotensin-converting enzyme (ACE) inhibitors.

**Dates:** Conducted from 1999 to 2003.

**Results:** The CHARM-Alternative trial showed that candesartan significantly reduced the risk of cardiovascular death or heart failure hospitalization compared to placebo in patients with heart failure intolerant to ACE inhibitors, with a good safety profile.

**Impact:** These results supported the use of Atacand in patients with heart failure who are intolerant to ACE inhibitors.

### **CHARM-Added Trial (Phase III)**

**Pubmed:** <https://pubmed.ncbi.nlm.nih.gov/13678869/>

**Purpose:** Evaluate the effect of adding candesartan or placebo to existing therapy in patients with heart failure and reduced ejection fraction.

**Dates:** Conducted from 1999 to 2003.

**Results:** The CHARM-Added trial demonstrated that adding candesartan to standard therapy significantly reduced the risk of cardiovascular death or heart failure hospitalization compared to placebo in patients with heart failure and reduced ejection fraction, with a good safety profile.

**Impact:** These results supported the use of Atacand as an add-on therapy in patients with heart failure and reduced ejection fraction.